LifeMD to Report Fourth Quarter 2023 Financial Results on March 11

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) — LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 months ended December 31, 2023 after the close of the U.S. financial markets on March 11, 2024 and will host a conference call beginning at 4:30 p.m. Eastern time.

Conference Call & Webcast Details

Date: Monday, March 11th
Time: 4:30 p.m. Eastern time
Toll-Free Dial-In: 1-877-704-4453
International Dial-In: 1-201-389-0920
Conference ID: 13743864
Live & Archived Webcast: Link
 

About LifeMD, Inc.
LifeMD is a leading provider of virtual primary care. LifeMD offers telemedicine, laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s health, women’s health, allergy & asthma, and dermatology. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to top-notch and affordable care. For more information, please visit LifeMD.com.

Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com

Media Contact
Jessica Friedeman, Chief Marketing Officer
press@lifemd.com

Staff

Recent Posts

Sona’s Cancer Therapy Triggers Abscopal Effect, Eliminating Distant Tumors In Preclinical Melanoma Study

Halifax, Nova Scotia--(Newsfile Corp. - June 26, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

2 hours ago

Bemax Inc. Announces UK Distribution Hub for Reduced Lead Time on Orders

Dallas, Georgia--(Newsfile Corp. - June 26, 2024) - Bemax Inc. (OTC Pink: BMXC), a private…

3 hours ago

Lifeward Unveils Newest Addition to Its AlterG Anti-Gravity Product Line – Introducing AlterG NEO

Elevate your practice and revolutionize patient care with the all-new user-friendly design and the same…

3 hours ago

BioStem Technologies Reports Breakthrough Results with AmnioWrap2® in Retrospective Wound Care Study

Study published in peer-reviewed journal finds BioStem’s products offer overall better treatment efficiency, and greater…

3 hours ago

Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK

AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage…

3 hours ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial

Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic CancerLOS ALTOS, Calif., June 26, 2024…

3 hours ago